Acelyrin — Merger or Acquisition (April 2025)
29 slides from Acelyrin's merger presentation, Apr 21, 2025
Slide 1: Investor Presentation April 2025
Exhibit 99.1 Investor Presentation April 2025
Slide 2: Disclaimer: Forward-Looking Statements
Disclaimer Forward-Looking Statements This communication contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expe
Slide 3: Executive Summary
Executive Summary The Alumis Merger Provides Significant Potential Upside For ACELYRIN Stockholders › The combination provides the opportunity to participate in the potential upside from Phase 3 data for Alumis’ lead program expected in 1Q26 and a combined pipeline with multiple upcoming milestones
Slide 4: The Alumis Merger Provides Significant Potential Upside For ACELYRIN Stockholders
The Alumis Merger Provides Significant Potential Upside For ACELYRIN Stockholders 4
Slide 5: At Time of IPO, Investors Expected a Robust Pipeline but Setbacks Impacted Growth
At Time of IPO, Investors Expected to Benefit from a Robust Pipeline but Several Clinical Setbacks and Management Departures Have Impacted Growth Prospects Overview Limited Pipeline Remaining From Time of IPO Stage at IPO › ACELYRIN IPO’d in May 2023 based on Phase 2b/3 Part A data for PC Ph1 Ph2 Ph
Slide 6: ACELYRIN Shares Under Significant Pressure Since Izokibep Data
ACELYRIN Shares Have Been Under Significant Pressure Since Phase 2b/3 Part B Izokibep Data in Hidradenitis Suppurativa (“HS”) in September 2023 › After additional readouts, Izokibep was deprioritized and ACELYRIN is focused on Lonigutamab › Lonigutamab has the potential to be a best-in-class next-ge
Slide 7: Lonigutamab Could Be a Differentiated Medicine in a Large and Growing Market
ACELYRIN’s Board Believes Lonigutamab has the Potential to be a Differentiated Medicine in a Large and Growing Market … Product Profile Market Opportunity Efficacy in-line with IV anti-IGF-1R agents Minimally penetrated U.S. market Proptosis response in line with others, within the limitations of a
Slide 8: Market Was Not Reflecting the Potential Upside for ACELYRIN
… And that the Market Was Not Reflecting the Potential Upside for ACELYRIN 1 ACELYRIN Equity Value / Equity Value Per Share Post-Ph3 TED Trading Comp $2.3B / $20.00 2 $1.9B $1.2B Enterprise Value $602M / $5.68 $448M / $4.28 $481M / $4.59 $199M / $1.90 $314M / $3.00 Implied Per Share Price Reflected
Slide 9: Significant Risk Exists for ACELYRIN Stock Price as a Standalone Company
Significant Risk Exists for ACELYRIN Stock Price as a Standalone Company in This Environment Relative Share Price Performance Since Announcement $3.00 “Nearly 200 companies trade below their cash value…” $2.20 16% $2.00 1 Select Biotech Stocks ($ in Millions) (19%) Mkt Cap less Cash Mkt Cap Cash ▼ %
Slide 10: Strategic Merger Key Terms
Strategic Merger Key Terms › All Stock Merger Consideration › ACELYRIN stockholders to receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned Pro Forma › Alumis stockholders to own approximately 52% of the combined company 1 Ownership › ACELYRIN stockholders to ow
Slide 11: With 48% Ownership, ACELYRIN Stockholders Participate in Upside Potential
With 48% Ownership in Combined Company, ACELYRIN Stockholders Have Ability to Participate in Significant Upside Potential › The strategic merger IS: A combination of strategically aligned I&I companies, creating a stronger company that is well-positioned to realize long-term value › The strategic me
Slide 12: Board Achieved Favorable Terms and Attractive Pro Forma Ownership
ACELYRIN’s Board Believes that it Achieved Favorable Terms and Attractive Pro Forma Ownership for ACELYRIN Stockholders (values in millions, except per share values) Alumis Discounted ACELYRIN Discounted 1 Cash Flow Analysis Exchange Ratio (Implied Ownership) Cash Flow Analysis Equity Value Equity V
Slide 13: Transaction Committee Secured Multiple Improvements in Economic Terms
The ACELYRIN Transaction Committee Secured Multiple Improvements in Economic Terms Despite a Declining ACELYRIN Share Price Original Improved Transaction Terms Transaction Terms Conducted rigorous, objective and Additional Ph1b/2 data and Ph3 Announced 2/6 Announced 4/21 competitive process includin
Slide 14: Combination Expected to Be Value Accretive to ACELYRIN Stockholders
The ACELYRIN Board Believes that the Combination with Alumis is Expected to be Value Accretive to ACELYRIN Stockholders Via Synergies, Scale and Shared Ownership of a Diversified Portfolio › Opportunity to participate in significant upside from 1Q26 ESK-001 pivotal readout and future Lonigutamab cat
Slide 15: Research Analyst Reactions Favorable Toward Merger Announcement
Research Analyst Reactions Were Favorable Toward The Strategic Merger Announcement, Even Prior to ACELYRIN Negotiating Improved Terms “We believe this [strategic merger] is a “It's refreshing to see a capital-efficient “Merger with SLRN relieves financing smart idea as it diversifies the assets and
Slide 16: Combination Creates a Leading Clinical-Stage Immunology Company
Combination Creates a Leading Clinical-Stage Immunology Company with a Diversified Portfolio of Product Candidates 16
Slide 17: Leading I&I Company with Upcoming Milestones and Runway into 2027
Creating a Leading I&I Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027 › Creates a late-stage clinical biopharma company dedicated to innovating, developing and commercializing transformative therapies for immune-mediated diseases › Differentiated pipelin
Slide 18: Late-Stage Pipeline with Multiple Near-Term Catalysts
Late-Stage Pipeline with Multiple Near-Term Catalysts Clinical Development Plan to be finalized mid-2025 Abbreviations: PsA = Psoriatic Arthritis; IBD = Inflammatory Bowel Disease; PAR = Parkinson’s Disease; AD = Alzheimer’s Disease. 18
Slide 19: Alumis Management Team Experience and Expertise
The Alumis Management Team has the Right Experience and Expertise to Effectively Deploy a Clinical Development Plan for Lonigutamab and Maximize the Value of the Full Pipeline Martin Babler John Schroer Jörn Drappa MD, PhD Jack Danilkowicz President, CEO and Chairman Chief Financial Officer Chief Me
Slide 20: Combined Company Offers Upside vs. Clinical-Stage Immunology Peers
The Combined Company Provides Multiple Late-Stage Assets and a Proven Leadership Team that Together Offers Significant Upside vs. Clinical-Stage Immunology Peers 1 2 Market Cap ($B) $0.5 $0.6 $0.8 $1.2 $1.3 $1.4 $2.0 $2.5 $2.6 1 3 Enterprise Value ($B) ($0.2) $0.4 $0.2 $0.5 $0.6 $0.8 $1.5 $2.0 $2.2
Slide 21: Independent Board Committee Ran a Thorough Process
Independent Board Committee Ran a Thorough Process to Review Multiple Alternatives and Optimize Terms From Alumis 21
Slide 22: Strategic Process Led by Independent Transaction Committee
Comprehensive ACELYRIN Strategic Process Led by a Highly Experienced and Accomplished Independent Transaction Committee Henry Gosebruch | Chairman of the Beth Seidenberg, MD Bruce C. Cozadd | Chairman of the Board Transaction Committee Founding Managing Director of Chairman and CEO of Jazz Pharmaceu
Slide 23: Disinterested and Independent Directors with Applicable Expertise
Supported by Disinterested and Independent Directors with Directly Applicable Expertise Dan Becker, MD, PhD Dawn Svoronos Lynn Tetrault, JD Managing Director, Former President of the Europe & Canada Former EVP of Human Resources and Access Biotechnology region for Merck & Co Corporate Affairs at Ast
Slide 24: Board Conducted a Rigorous, Objective and Competitive Process
The ACELYRIN Board Conducted a Rigorous, Objective and Competitive Process Board undertook an extensive process that began in 2Q 2024 and resulted in the proposed strategic merger with Alumis This process included interactions with ~25 potential counterparties and the exploration of a wide variety o
Slide 25: Board Focused on Intrinsic Value While Monitoring Implied Market Value
The ACELYRIN Board was Focused on Intrinsic Value and Value-Creation Potential, but Also Closely Monitored the Implied Market Value $12.00 Strategic Merger Strategic Merger Proxy Publicly Filed Announcement $10.00 Alumis $8.22 $8.00 $6.59 $6.00 ACELYRIN $5.00 Implied consideration Implied considerat
Slide 26: Board Did Not Believe Tang Acquisition Would Lead to Superior Proposal
The ACELYRIN Board Did Not Believe the Tang Acquisition Would Lead to a Superior Proposal › In accordance with its fiduciary duties, the ACELYRIN Board thoroughly evaluated and considered the Tang Proposal at the time of receipt, with the assistance of outside legal and financial advisors › Specific
Slide 27: The Combination Could Be Transformative to ACELYRIN's Business
The Combination Could Be Transformative to ACELYRIN’s Business Standalone ACELYRIN Combined Company • ESK-001 • Lonigutamab Deep Pipeline of Product Candidates • Lonigutamab • A-005 Differentiated Assets • IRF5 • Additional Targets • Mid-2025: Finalize Plan for Lonigutamab Multiple • 2H25: A-005 – M
Slide 28: Strategic Merger with Alumis Is Value Maximizing for Stockholders
The ACELYRIN Board Believes that the Strategic Merger with Alumis is Value Maximizing for ACELYRIN Stockholders The Alumis Merger Provides Significant Potential Upside For ACELYRIN Stockholders › The combination provides the opportunity to participate in the potential upside from Phase 3 data for Al
Slide 29: Vote For the Merger Proposal
VOTE FOR THE MERGER PROPOSAL VOTE FOR COMPELLING VALUE FOR ACELYRIN STOCKHOLDERS For more information or assistance with voting your shares, please contact our proxy solicitor: Sodali & Co 333 Ludlow Street, 5th Floor, South Tower Stamford, CT 06902 Email: SLRN@investor.sodali.com Toll-Free: (800) 6